Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma

Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma

BackgroundRelapsed or refractory central nervous system lymphoma (rrCNSL) lacks established preferred treatment and carries an inferior prognosis. Bruton’s tyrosine kinase inhibitor (BTKi) showed promising effectiveness. Orelabrutinib is a second-generation BTKi with a high concentration in cerebros...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuchen Wu, Xuefei Sun, Liwei Lv, Qu Cui, Jun Qian, Ruixian Xing, Xueyan Bai, Yuedan Chen, Qing Liu, Wenyuan Lai, Chunji Gao, Shengjun Sun, Nan Ji, Yuanbo Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Neurology
Subjects:
central nervous system lymphoma
relapsed or refractory
Bruton’s tyrosine kinase inhibitor
orelabrutinib
methotrexate
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2025.1570224/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2025.1570224/full

Similar Items